long intergenic non-protein coding RNA 1825Genealiases: []
Q-omics provides the consensus-scored LINC01825 profile across patient tissues and cancer cell-line models. LINC01825 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01825 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC01825 RNA expression shows 12,481 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight MESO, KIRC, and DLBC as cancer lineages where LINC01825 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01825 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01825 survival associations across molecular data types. LINC01825 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01825 RNA expression–survival associations across cancer types. High LINC01825 expression shows unfavorable associations in MESO, UCS, DLBC and KIRC, but favorable associations in ESCA and OV. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01825 RNA expression.
This table summarizes LINC01825 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01825. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01825 shows lower tumor expression in BLCA, ESCA and HNSC and higher tumor expression in KIRC, KICH and LUAD. The KIRC box plot shows higher LINC01825 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .001).
This table shows molecular features associated with LINC01825 in patient tissues and cancer cell lines. In patient samples, LINC01825 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
